logo-loader

Full interview: Arecor completes dosing in its Phase I clinical trial and secures key partnership

Published: 10:21 06 Nov 2019 EST

Arecor's Sarah Howell tells Proactive London's Andrew Scott they've now completed dosing and patient visits in the Austria-based phase I study of its ultra-rapid acting insulin candidate, AT247, with results expected by the end of the year.

They've also signed a research, development and commercialisation deal with JDRF - the world's leading type 1 diabetes research charity.

FTSE 100 awaits Rishi Sunak’s Budget today while oil majors rise with higher...

FTSE 100 opened higher helped by a strong start from the oil majors BP and Shell as more brokers predicted crude prices are going to rise higher. Attention will focus on Rishi Sunak’s Budget later today but for now the index is up 38 at 7,515.   Sunak’s announcement comes just after UK...

on 03/23/2022